Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01996007
Other study ID # OVG 2013/05
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 2014
Est. completion date August 2015

Study information

Verified date November 2015
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pneumococcus is a bacteria that causes disease of the respiratory tract (pneumonia and middle ear infections), blood poisoning, and meningitis. It is frequently carried by people in back of the throat without symptoms. Pneumococcal carriage in the Thames Valley region has been studied over the last 12 years with carriage rates having been shown to be reflective of disease potential and hence vaccine effect. During this time pneumococcal vaccines have been introduced into the routine immunisation schedules of this community. The PCV7 (A vaccine against 7 types of pneumococcus) vaccine has subsequently been noted to have had a significant impact in reducing vaccine serotype carriage and disease. Herd protection (indirect protection of unvaccinated individuals) has also been implicated with vaccine serotypes not being carried in parents of vaccinated children. The most common serotype carried since the introduction of PCV7 is 19A, which is included in the PCV13 vaccine (A vaccine against 13 types of pneumococcus). PCV13 has superseded PCV7 in the routine immunisation schedule, however its impact on carriage and disease in this community is yet to be evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 1200
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria:

Children

- Parent/guardian of participant is willing and able to give informed consent for participation in the study.

- In good health as determined by a brief medical history and/or clinical judgement of the investigator

- Have received three doses of PCV13 as per infant immunisation schedule (as confirmed by red book or through vaccination history and age). Vaccination history will be confirmed by the child's GP or CHCD. The visit and sampling may still proceed if the vaccination history has not been confirmed beforehand and the participant subsequently excluded if they are found to not have received all three doses of PCV13.Aged 6-48 months and at least 28 days since their third PCV13 vaccination.

- Able (in the Investigators opinion) and willing to comply with all study requirements.

Parents/ Legal guardians

- Participant is willing and able to give informed consent for participation in the study.

- Is the child's legal guardian and lives in the same household with the child participating in the same study.

- In good health as determined by clinical judgement of the research staff

- Able (in the investigators opinion) and willing to comply with all study requirements.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

Children

- Parent/legal guardian unwilling or unable to give written informed consent to participate in the study.

- Parent/legal guardian less than 18 years of age at time of enrolment.

- Parent/legal guardian is listed on the study delegation log.

- Children who are unimmunised or have an incomplete course of PCV13.

- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

- Febrile illness or temperature of 38°C on the day of the visit or in the preceding 24 hours.

- Respiratory illness on the day of the study visit or in the preceding 24 hours. A respiratory illness will be classified as a combination of at least two of the following symptoms: cough, sore throat, and runny nose.

- Administration of antibiotics in the month prior to sampling.

- A risk of nose bleed, including; a recent (within the last 24 hours) nose bleed, history of a bleeding disorder, history of severe nose bleeds or recent (within the last 3 months) nasal/craniofacial surgery.

- Receipt of blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days.

Parents/ Legal guardians

- Participants who are unwilling or unable to give written informed consent to participate in the study.

- Less than 18 years of age at time of enrolment

- Is listed on the study delegation log

- Previous immunisation with pneumococcal conjugate vaccine.

- Participants who in the opinion of the investigator are unable to comply with study procedures or may be put at risk by participation in the study.

- Febrile illness or temperature of 38°C on the day of the visit or in the preceding 24 hours.

- Respiratory illness on the day of the study visit or in the preceding 24 hours. A respiratory illness will be classified as a combination of at least two of the following symptoms: cough, sore throat, and runny nose.

- Administration of antibiotics in the month prior to sampling.

- A risk of nose bleed, including; a recent (within the last 24 hours) nose bleed, history of a bleeding disorder, a history of severe nose bleeds or recent (within the last 3 months) nasal/craniofacial surgery.

- Receipt of blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Oxford Vaccine Group Oxford Oxfordshire

Sponsors (2)

Lead Sponsor Collaborator
University of Oxford Pfizer

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, Hughes H, Ndimah S, Gould K, Fry N, Sheppard C, Ladhani S, Snape MD, Hinds J, Pollard AJ. Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant i — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The presence of serotype 19A pneumococci on children's swabs 2 years
Secondary The presence of pneumococcal serotypes on children's swabs 2 years
Secondary The presence of pneumococcal serotypes on parents/legal guardians swabs 2 years
Secondary The molecular sequence type of nasopharyngeal carriage isolates from children and parents/legal guardians. 2 years
Secondary The serotype-specific and genotype-specific invasive disease potential of isolates recovered from children. 2 years
Secondary The serotype specific pneumococcal antibodies levels in children and their parents/legal guardians 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4